(Reuters) - Airbus, the biggest shareholder in French artificial heart maker Carmat, said on Wednesday it was aware of Carmat's financial difficulties.
Airbus, the biggest
shareholder in French artificial heart maker Carmat,
said on Wednesday it was aware of Carmat s financial
difficulties but did not say whether it would support a.
(Reuters) - Airbus, the biggest shareholder in French artificial heart maker Carmat, said on Wednesday it was aware of Carmat's financial difficulties.
Global Offering aimed at specialized and strategic investors, as well as individual investors via the PrimaryBid platform Issue price of new shares at 10.0 euros per share Closing of
Shares surge (Adds quote, details)
PARIS, Jan 6 (Reuters) - Artificial heartmaker Carmat will begin sales of its devices from the second quarter of this year after a long-awaited European Commission approval, in a boost to its shares.
Given recurring shortages of donors, Carmat’s device aims to give patients with end-stage biventricular heart failure, a deadly condition where the heart is no longer able to pump blood adequately around the body, an alternative to hospital stays.
Although France’s Carmat has yet to generate any significant revenue, its devices could represent a major breakthrough as heart diseases represent a leading cause of death worldwide.